Liminatus Pharma, Inc. (LIMN)
| Market Cap | 6.27M -92.8% |
| Revenue (ttm) | n/a |
| Net Income | -12.52M |
| EPS | -18.06 |
| Shares Out | 1.34M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 82,775 |
| Open | 5.030 |
| Previous Close | 5.160 |
| Day's Range | 4.610 - 5.040 |
| 52-Week Range | 4.610 - 179.990 |
| Beta | 0.74 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 14, 2026 |
About LIMN
Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer. The company was founded in 2018 and is based in Cerritos, California.
Financial Performance
Financial StatementsNews
Liminatus Pharma engages Synex Consulting to support IBC101 development
Liminatus Pharma (LIMN) announced that it has engaged Synex Consulting to support the clinical development of IBC101, the company’s CD19xCD22 bivalent CAR-T cell therapy candidate. IBC101 has received...
Liminatus Pharma Engages Synex as Contract Research Organization to Support Phase 1/2a Clinical Development of CD19xCD22 bivalent CAR-T therapy
FULLERTON, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (Nasdaq: LIMN) (“Liminatus” or the “Company”), a biotechnology company developing innovative cancer therapies, today announc...
Liminatus Pharma Inc trading halted, news pending
19:50 EDT Liminatus Pharma (LIMN) Inc trading halted, news pending
Liminatus Pharma announces 1-for-50 reverse stock split
Liminatus Pharma announced that its board of directors has adopted resolutions approving a reverse stock split of its common stock, par value 1c per share, at a ratio of 1-for-50,…
Liminatus Pharma, Inc. Announces Reverse Stock Split of its Common Stock
FULLERTON, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (Nasdaq: LIMN) (“Liminatus” or the “Company”) today announced that its board of directors has adopted resolutions approving ...
Liminatus Pharma (LIMN) Stock Jumps Over 50% on a Listing Update
Liminatus Pharma stock was up 53.09% on Thursday after the company provided investors with a listing update.
Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Compliance with Minimum Bid Price Requirement
FULLERTON, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (Nasdaq: LIMN) (“Liminatus” or the “Company”), a biopharmaceutical company developing novel therapies for cancer and other s...
Liminatus Pharma amends, restates merger agreement with InnocsAI
Liminatus Pharma (LIMN) announced that it has amended and restated the previously announced definitive merger agreement with InnocsAI. The transaction has been re-structured to allow closing prior to ...
Liminatus Pharma Amends Definitive Merger Agreement with InnocsAI to Expand Oncology Cell Therapy Pipeline
FULLERTON, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (Nasdaq: LIMN) ("Liminatus" or the "Company"), a biotechnology company developing innovative cancer therapies, today announc...
Liminatus Pharma files to sell 20.69M shares of common stock for holders
06:03 EDT Liminatus Pharma (LIMN) files to sell 20.69M shares of common stock for holders
Liminatus Pharma Enters Into Warrant Exercise Transaction for $1.9 Million in Gross Proceeds
FULLERTON, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (Nasdaq: LIMN) (“Liminatus” or the “Company”) today announced that it has entered into a warrant exercise agreement with exi...
Liminatus Pharma receives Nasdaq delisting notice
Liminatus Pharma (LIMN) announced that the company received a delisting notice from The Nasdaq Stock Market. On May 20, the company received a notice from Nasdaq stating that the company…
Liminatus Pharma Announces Nasdaq Delisting Notification
FULLERTON, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (Nasdaq: LIMN) (“Liminatus” or the “Company”) today announced that the Company received a delisting notice from The Nasdaq St...
Liminatus Pharma to initiate Phase 1 clinical trial for IBA101 antibody
Liminatus plans to initiate a Phase 1 clinical trial evaluating IBA101, a next-generation CD47-blocking monoclonal antibody designed to engage innate immune pathways and complement established immuno-...
Liminatus Pharma Announces Planned Phase 1 Clinical Trial of IBA101, a Next-Generation CD47 Blocking Antibody
CERRITOS, Calif., March 17, 2026 (GLOBE NEWSWIRE) -- Liminatus today announced plans to initiate a Phase 1 clinical trial evaluating IBA101, a next-generation CD47-blocking monoclonal antibody designe...
Liminatus Pharma prices 13.8M shares at 29c in public offering
Liminatus Pharma (LIMN) announced the pricing of its best-efforts public offering of 13,813,000 shares of its common stock and warrants to purchase up to 20,719,500 shares of common stock, at…
Liminatus Pharma, Inc. Announces Pricing of $4.0 Million Public Offering
CERRITOS, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ: LIMN) (“Liminatus” or the “Company”), a pre-clinical stage immuno-oncology company developing next-generation CD47-b...
Liminatus Pharma files to sell 6.9M shares of common stock, warrants
Maxim Group is exclusive placement agent for the offering.
Liminatus Pharma, Inc. (NASDAQ: LIMN) Signs MOU with Capital Trust Group for USD 30 Million Equity Investment via an earn-out mechanism and Future Strategic Cooperation
LA PALMA, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ: LIMN), a clinical-stage immuno-oncology company developing next-generation CD47-blockade therapies, announced today ...
Liminatus Pharma Inc trading resumes
13:26 EDT Liminatus Pharma (LIMN) Inc trading resumes
Liminatus Pharma Inc trading halted, volatility trading pause
13:21 EDT Liminatus Pharma (LIMN) Inc trading halted, volatility trading pause
Liminatus Pharma to launch ‘American BNB Strategy’ subsidiary
Liminatus Pharma (LIMN) announced plans for a strategic expansion into the cryptocurrency and blockchain sector. The company intends to establish a dedicated subsidiary, named “American BNB Strategy,”...
Liminatus Pharma Inc. to Launch “American BNB Strategy” Subsidiary and Target Up To $500 Million Fund for BNB Investment as Part of Crypto Market Initiative
Liminatus Identifies BNB Coin as Its Primary Strategic Target for Digital Asset Allocation, with Plans to Aggressively Accumulate and Hold Up to $500 Million for Long-Term Strategic Value Liminatus Id...
Liminatus Pharma evaluates formation of digital asset investment vehicle
Liminatus Pharma (LIMN) announced that its Board of Directors and executive team have formally initiated a strategic review to explore the potential formation of a dedicated digital asset investment v...
Liminatus Pharma Inc. Evaluates Formation of Digital Asset Investment Vehicle Targeting Up To $500 Million in Capital Strategies
Strategic Internal Review initiated for treasury diversification through a prospective digital asset subsidiary — no entity formed, no capital committed Strategic Internal Review initiated for treasur...